CD274 and non-small cell lung carcinoma: Immunotherapeutic agents currently used in NSCLC include programmed death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) (73).